Semaglutide

MRI‑PDFF subanalysis (n=55) found mean liver fat fell from 8.8% to 3.1% at week 72; 88.5% with baseline liver fat >5% reached <5%.

Ro telehealth real-world data: mean 4.1% weight loss at three months; 40.7% reached ≥5% loss; obesity (BMI≥30) prevalence fell 21.6 percentage points; N=194.

fMRI shows reduced ‘food noise’ and cravings; trials report major weight loss, reductions in abdominal/liver/pancreas fat and preliminary bone‑marker reassurance.

Real-world claims analysis found escalating from semaglutide 1 mg to 2 mg tied to a 6% lower risk of major adverse cardiovascular events than switching to tirzepatide.

An indirect, covariate‑adjusted comparison of SURMOUNT‑1 and STEP UP data shows larger mean and categorical weight‑loss benefits with tirzepatide 10 mg and 15 mg at 72 weeks.

CagriSema 1.0/1.0 delivered greater weight loss than tirzepatide 5 mg and 21% vs 2% vs placebo in obesity trial; HbA1c reduction was non‑inferior. FDA decision expected Q4 2026.

Phase 3 retatrutide and Foundayo results show large weight and A1C reductions and signals of cardiovascular benefit; Phase 2 eloraTZP and additional Mounjaro/Zepbound analyses also presented.

OASIS data showed ~17% mean weight loss and ~1 in 3 reached ≥20%; safety comparable to injectable semaglutide; wider roll‑out planned in H2 2026.

Daily 25 mg semaglutide tablet approved as adjunct to diet and exercise for adults with obesity or overweight plus a weight‑related condition; private prescriptions expected soon.

Oral GLP‑1 orforglipron reduced A1C and body weight more than oral semaglutide, dapagliflozin or placebo across three Phase‑3 trials; FDA filing planned by end of Q2 2026.